Effects Of China-U.S. Safety Pact On U.S. Companies

Law360, New York (January 18, 2008, 12:00 AM EST) -- On Dec. 11, 2007, the United States Department of Health and Human Services (DHHS) and the People’s Republic of China State Food and Drug Administration (SFDA) signed a Memorandum of Understanding (MOU) regarding the safety of specific drugs and medical devices traded between the countries.

This MOU may affect U.S. companies that export recombinant human insulin, lysine, cefoperazone, paclitaxel, penicillin, diagnostic kits for blood screening (including those for HIV/AIDS and hepatitis B & C), intraocular lenses and cardiac pacemakers into China.

It also could affect U.S....
To view the full article, register now.